Dosage Regimen of Vancomycin and the Effect of Education and Providing Advice to Physicians by Pharmacists on Vancomycin in Medical Intensive Care Units at King Chulalongkorn Memorial Hospital
Article Sidebar
Main Article Content
Abstract
Objective: To study dosage regimen of vancomycin used and the effect of education and providing advice to physicians by pharmacists in Medical Intensive Care Units (MICUs) at King Chulalongkorn Memorial Hospital, The Thai Red Cross Society (KCMH). Method: This study was a 12-month retrospective descriptive study in patients aged 18 years and over treated with vancomycin in MICUs ward at KCMH. Pharmacists provided knowledge to physicians in MICU ward on loading dose of vancomycin use and therapeutic drug monitoring, and monitored patients prescribed with vancomycin. The study collected the information on dosage regimen of vancomycin, vancomycin levels, and pharmacists’ advices such as dosage adjustments, drug level monitoring, and percentage of the acceptance of advices. Results: The study collected data from a total of 85 patients (105 prescriptions). Patients were 56.47% male with mean age 66.55 ± 17.44 years. First prescribing of vancomycin was for an empirical therapy (78.10%). 51.90% of the patients received a loading dose of 20-35 mg/kg. Trough vancomycin level (Ctrough) in the range of 10-20 mg/l was found in 56.98% of patients. After vancomycin treatment, there was a statistically insignificant increase in serum creatinine (P=0.57). A total of 11 recommendations were given by the pharmacists and all were accepted. Conclusion: Pharmacists’ advices on appropriate loading dose of vancomycin resulted in patients having Ctrough of vancomycin within the target range.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
ผลการวิจัยและความคิดเห็นที่ปรากฏในบทความถือเป็นความคิดเห็นและอยู่ในความรับผิดชอบของผู้นิพนธ์ มิใช่ความเห็นหรือความรับผิดชอบของกองบรรณาธิการ หรือคณะเภสัชศาสตร์ มหาวิทยาลัยสงขลานครินทร์ ทั้งนี้ไม่รวมความผิดพลาดอันเกิดจากการพิมพ์ บทความที่ได้รับการเผยแพร่โดยวารสารเภสัชกรรมไทยถือเป็นสิทธิ์ของวารสารฯ
References
Köck R, Becker K, Cookson B, van Gemert-Pijnen J, Harbarth S, Kluytmans J, et al. Methicillin-resistant Staphylococcus aureus (MRSA): burden of disease and control challenges in Europe. Eurosurveillance. 2010; 15: 19688.
Hanberger H, Walther S, Leone M, Barie PS, Rello J, Lipman J, et al. Increased mortality associated with meticillin-resistant Staphylococcus aureus (MRSA) infection in the intensive care unit: Results from the EPIC II study. Int J Antimicrob Agents. 2011; 38: 331-5.
Abdul-Aziz MH, Alffenaar J-WC, Bassetti M, Bracht H, Dimopoulos G, Marriott D, et al. Antimicrobial therapeutic drug monitoring in critically ill adult patients: A position paper. Intensive Care Med. 2020; 46: 1127-53.
Barna J, Williams D. The structure and mode of action of glycopeptide antibiotics of the vancomycin group. Annu Rev Microbiol. 1984; 38: 339-57.
Levine DP. Vancomycin: a history. Clin Infect Dis. 2006; 42(Supplement_1): S5-S12.
Rybak MJ, Le J, Lodise TP, Levine DP, Bradley JS, Liu C, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2020; 77: 835-64.
Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med. 2009; 37: 840-51.
Ye Z-K, Tang H-L, Zhai S-D. Benefits of therapeutic drug monitoring of vancomycin: a systematic review and meta-analysis. PloS one. 2013; 8: e77169.
Hirano R, Sakamoto Y, Kitazawa J, Yamamoto S, Tachibana N. Pharmacist-managed dose adjustment feedback using therapeutic drug monitoring of vancomycin was useful for patients with methicillin-resistant Staphylococcus aureus infections: a single institution experience. Infect Drug Resist. 2016; 9: 243.
Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta J-P, Del Zotti F, et al. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC)Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J. 2015; 36: 3075-128.
Rybak MJ, Lomaestro BM, Rotscahfer JC, Moellering RC, Jr., Craig WA, Billeter M, et al. Vancomycin Therapeutic Guidelines: A Summary of Consensus Recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis. 2009; 49: 325-7.
Organization WH. Defined Daily Dose (DDD) [online]. 2020 [cited July 8, 2022]. Available from: www.who.int/toolkits/atc-ddd-toolkit/about-ddd.
Morris AM, Brener S, Dresser L, Daneman N, Dellit TH, Avdic E, et al. Use of a structured panel process to define quality metrics for antimicrobial stewardship programs. Infect Control Hosp Epidemiol. 2012; 33: 500-6.
Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985; 13: 818-29.
Bone RC, Balk RA, Cerra FB, et al. American College of Chest Physicians/Society of Critical Care
Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20: 864-74.
Kaukonen K-M, Bailey M, Pilcher D, Cooper DJ, Bellomo R. Systemic inflammatory response syndrome criteria in defining severe sepsis. N Engl J Med. 2015; 372: 1629-38.
Abdul-Aziz MH, Sulaiman H, Mat-Nor M-B, Rai V, Wong KK, Hasan MS, et al. Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis. Intensive Care Med. 2016; 42: 1535-45.
Alshehri N, Ahmed AE, Yenugadhati N, Javad S, Al Sulaiman K, Al-Dorzi HM, et al. Vancomycin in ICU patients with gram-positive infections: Initial trough levels and mortality. Ther Clin Risk Manag. 2020; 16: 979.
Ueda T, Takesue Y, Nakajima K, Ichiki K, Ishikawa K, Takai Y, et al. Vancomycin loading dose is associated with increased early clinical response without attainment of initial target trough concentration at a steady state in patients with methicillin-resistant Staphylococcus aureus infections. J Clin Pharm Ther. 2020; 45: 682-90.
Cotta M, Roberts J, Lipman J. Antibiotic dose optimization in critically ill patients. Med Intensiva. 2015; 39: 563-72.
Truong J, Levkovich B, Padiglione A. Simple approach to improving vancomycin dosing in intensive care: a standardised loading dose results in earlier therapeutic levels. Internal Med J. 2012; 42: 23-9.
Hodiamont C, Juffermans N, Berends S, van Vessem D, Hakkens N, Mathôt R, et al. Impact of a vancomycin loading dose on the achievement of target vancomycin exposure in the first 24 h and on the accompanying risk of nephrotoxicity in critically ill patients. J Antimicrob Chemother. 2021; 76: 2941-9.
DeRyke CA, Alexander DP. Optimizing vancomycin dosing through pharmacodynamic assessment targeting area under the concentration-time curve/minimum inhibitory concentration. Hosp Pharm. 2009; 44: 751-65.
